Home › Chronic Myeloid Leukemia › Oregon
Chronic Myeloid Leukemia clinical trials in Oregon
6 studies for Chronic Myeloid Leukemia are looking for participants at sites in Oregon.
Cities in Oregon
Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1139, Portland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06423911Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- and 8 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- Oregon Health & Science University-Knight Cardiovascular Institute, Portland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT05304377A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- Willamette Valley Cancer Institute and Research Center, Eugene
- Oregon Health & Science University, Portland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 12, 2026 · NCT06163430From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.